Park Juhyun, Kwon Ohseong, Cho Sung Yong, Cho Min Chul, Paick Jae Seung, Kim Soo Woong
Department of Urology, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
Department of Urology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
World J Mens Health. 2019 May;37(2):210-218. doi: 10.5534/wjmh.180057. Epub 2018 Nov 27.
To compare the improving effects of diabetic erectile dysfunction with two anti-glycemic agents; phlorizin and insulin.
Sixty Sprague-Dawley rats were divided into four groups (n=15 in each group): normal control (C), untreated diabetic rats (D), and diabetic rats treated by phlorizin (P) or insulin (I). Ten weeks after the diabetic induction using an injection of streptozotocin (55 mg/kg), four weeks of diabetic control was conducted. Erectile response, Western blot, and immunohistochemistry were assessed.
During the experiment, the C-group showed continuous weight gain, while the other groups suffered from weight loss. After start of diabetic control, the body weight of I-group was increased; whereas, there was no meaningful change in the P-group. Meanwhile, comparable blood glucose levels were achieved in the P- and I-groups. The erectile response was markedly decreased in the D-group, whereas the P- and I-groups were similar as good as the C-group. In addition, D-group showed the significant decrease in the cavernosal smooth muscle content and increased apoptosis. Platelet endothelial cell adhesion molecule-1 protein expression, phosphorylation of endothelial nitric oxide synthase and myosin phosphatase target subunit 1 were significantly distorted in the D-group, while the P- and I-groups were comparable with the C-group.
Phlorizin treatment resulted in the improvement of erectile function as same as insulin despite the lack of anabolic weight gains. These results suggest that control of blood glucose level rather than a type of anti-glycemic agents is more important for the prevention and treatment of diabetic erectile dysfunction.
比较两种抗糖尿病药物根皮苷和胰岛素对糖尿病性勃起功能障碍的改善效果。
将60只Sprague-Dawley大鼠分为四组（每组n = 15）：正常对照组（C）、未治疗的糖尿病大鼠组（D）、根皮苷治疗的糖尿病大鼠组（P）和胰岛素治疗的糖尿病大鼠组（I）。通过注射链脲佐菌素（55 mg/kg）诱导糖尿病10周后，进行4周的糖尿病控制。评估勃起反应、蛋白质免疫印迹法和免疫组织化学。
实验期间，C组体重持续增加，而其他组体重减轻。糖尿病控制开始后，I组体重增加；而P组体重无明显变化。同时，P组和I组的血糖水平相当。D组的勃起反应明显降低，而P组和I组与C组相似，效果良好。此外，D组海绵体平滑肌含量显著降低，细胞凋亡增加。D组血小板内皮细胞黏附分子-1蛋白表达、内皮型一氧化氮合酶磷酸化和肌球蛋白磷酸酶靶亚基1显著异常，而P组和I组与C组相当。
尽管根皮苷治疗没有促进体重增加的合成代谢作用，但与胰岛素一样能改善勃起功能。这些结果表明，对于糖尿病性勃起功能障碍的预防和治疗，控制血糖水平比抗糖尿病药物的类型更重要。
